global-hematology-2019-scientifictracks

3 / 7

Hematology and Blood Disorders | Volume 2
Page 18
July 25-26, 2019 | Amsterdam, Netherlands
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Global Hematology 2019
4th International Conference on
HEMATOLOGY AND
BONE MARROW TRANSPLANTATION
GLOBAL RESPONSE ASSESSMENT BY ADVANCED IMAGING AND MYELOMA LESION
BIOPSIES DURING INDUCTION THERAPY OF MULTIPLE MYELOMAWITH CARFILZOMIB
LENALIDOMIDE DEXAMETHASONE (CRD)
Natalia Neparidze, Stuart Seropian, Terri Parker, Noffar Bar, Tara Anderson, Julie Baker, Alfred Lee,
Nikolai Podoltsev, Stephanie Halene, Mina Xu, Wei Wei, Andrew Lischuk, Brittany Branson and
Andrew Haims
Yale University, USA
Background: Despite multiple advances in the treatment multiple myeloma (MM) remains an incurable he-
matologic malignancy. MM is a multi-focal process with heterogeneous involvement of skeleton and/or soft
tissues. Focal myeloma lesions identified by advanced imaging may be the sanctuary sites of residual disease
after treatment. In this study author systematically evaluate response by using whole body MRI (WB-MRI) and
guided myeloma lesion biopsies to optimize assessment of response. They hypothesize that response assess-
ment withWB-MRI and myeloma lesion biopsy will increase the detection rate of residual/refractory disease by
about 20%, as compared with standard response evaluation.
Methods: This is a prospective single arm study for patients with newly diagnosed MM. All patients undergo a
standard bone marrow (BM) biopsy, skeletal survey, WB-MRI and guided myeloma lesion biopsy at study entry.
All patients receive an induction therapy with four cycles of carfilzomib, lenalidomide and dexamethasone
(CRD) regimen. After completion of induction, all patients undergo MM response assessment using standard
methods, as well as with repeat WB-MRI and guided biopsy of any residual MM lesions. They anticipate enroll-
ing 35 patients on this study. Preliminary data from interim analysis of the study are presented.
Results: To date, eight subjects have been enrolled. Three subjects have completed treatment and all of them
have achieved very good partial response (VGPR) or better. Of note, complete responses as assessed by WB-
MRI and lesion biopsies have been observed. Thus far, at study entry 50% of patients are identified to have
differential findings in morphology, cytogenetics and FISH when BM biopsies versus guided lesion biopsies are
compared.
Conclusion: They expect this method of response assessment with advanced imaging and myeloma lesion
biopsy will lead to improved response assessment in MM. This approach will help identify patients with large
residual disease burden and this in turn will lead to better risk-stratification of patients prior to autologous
stem cell transplant.
Natalia Neparidze et al., Hematol Blood Disord 2019, Volume 2
Natalia Neparidze obtained Medical Degree from AIETI Medical School in Tbilisi, Georgia; subsequently completed Postdoctoral
Research Fellowships at Emory, North western and Yale Universities, followed Residency and Hematology/Medical Oncology Fel-
lowship at Yale University. She has served as an Assistant Professor at Yale University School of Medicine since 2012 with research
focus on multiple myeloma. Her work has been widely published in peer-reviewed journals. She serves as a principal investigator
on multiple clinical trials in myeloma.
BIOGRAPHY